SCHEMBL9928639

SCHEMBL9928639

Cc1nnnn1N=Cc1ccc(O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 6/20 0.48
HPGD P15428 3/20 0.48
HSD17B10 Q99714 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
AMY1A P0DUB6 1/20 0.47
GFER P55789 1/20 0.45
MAPT P10636 4/20 0.44
KMT2A Q03164 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 3/20 0.44
POLB P06746 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
GAA P10253 3/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vp-14637 SCHEMBL20741449 0.81 GAA (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
Vp-14637 SCHEMBL29351615 0.81 GAA (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL7070861 0.81 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL7067443 0.81 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
Vp-14637 SCHEMBL16743389 0.81 GAA (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL7068147 0.77 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL10106495 0.73 GAA (0.45) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL642652 0.71 GAA (0.43) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL22788662 0.70 KDM4E (0.49) ALDH1A1KDM4EHPGDHSD17B10AMY1A
SCHEMBL24727973 0.65 AMY1A (1.00) ALDH1A1KDM4EHPGDHSD17B10AMY1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321739-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2016-04-26 US disclosed
US-8202896-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-06-19 US disclosed
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES RYS DAVID J (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305666-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, PML ALDH1A1 3369/4885KDM4E 4428/4885HPGD 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.